Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia

What Was Tested

The paper reports a study of Macimorelin (non-peptide), published as a randomized controlled trial.

Growth hormone secretagogues like macimorelin have potential to mitigate these effects.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, placebo-controlled and pilot study.

The participants were allocated by chance, so the Macimorelin (non-peptide) group and the comparison group should start out alike.

Some participants received a placebo instead of Macimorelin (non-peptide), giving a reference point.

It is described as a pilot, a small early test of whether a larger Macimorelin (non-peptide) study would be practical.

Secondary outcomes included food intake, appetite, functional performance, energy expenditure and safety laboratory parameters.

What Was Measured

The subject headings attached to it are Cachexia, Insulin-Like Growth Factor I, Quality of Life, Pilot Projects, Neoplasms, Indoles and Tryptophan.

Author keywords: appetite, cancer cachexia, ghrelin receptor agonist, growth hormone secretagogue and macimorelin.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and pilot study of Macimorelin (non-peptide).

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Journal of cachexia, sarcopenia and muscle), a journal based in Germany.

More context: the Macimorelin (non-peptide) compound page, all human trials.